Jagsonpal Pharmaceuticals Limited — Others, 02-04-2025: Action(s) initiated or orders passed

Jagsonpal Pharmaceuticals Limited has announced a board meeting to discuss the recent ruling from the Office of the Principal Commissioner of Customs, confirming a differential duty of ₹5.09 crore plus a penalty and interest for alleged incorrect classification of imported goods. The company plans to appeal the decision, expressing confidence in its classification practices and anticipating no material impact on its financials or operations. This outlook may provide reassurance to investors regarding the company's governance and risk management in compliance-related matters.